Analysis demonstrates differences in brca1, brca2, and hrd-scores between long- and short-term survivors in tubo-ovarian cancer cohorts, suggesting potential genetic implications.
Table S5 depicts the BRCA1/2, KRAS Status and HRD-Scores in LTS and STS in the Charité Cohort.
No takes yet. Share an insight, caveat, or question.
Marchenko et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: